Comparison

Pramlintid vs. VK2735

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Pramlintid	VK2735
Germany	Unapproved	Unapproved
United States	Prescription	Unapproved

Full entries

Frequently asked questions

What is the difference between Pramlintid and VK2735?: Pramlintid is classified as "Metabolic", while VK2735 is classified as "Metabolic". Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pramlintid or VK2735?: The highest available evidence level is "Human RCT" for Pramlintid and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pramlintid and VK2735 in Germany and the United States?: Germany: Pramlintid — Unapproved, VK2735 — Unapproved. United States: Pramlintid — Prescription, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Pramlintid

VK2735

Germany

Unapproved

United States

Prescription

Unapproved

Frequently asked questions

What is the difference between Pramlintid and VK2735?

Pramlintid is classified as "Metabolic", while VK2735 is classified as "Metabolic". Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pramlintid or VK2735?

The highest available evidence level is "Human RCT" for Pramlintid and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pramlintid and VK2735 in Germany and the United States?

Germany: Pramlintid — Unapproved, VK2735 — Unapproved. United States: Pramlintid — Prescription, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.